ArticleWorld journal of hepatology2013
Increased bone mineral density in patients with non-alcoholic steatohepatitis.
Article in World journal of hepatology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 28 citations in OpenAlex.
- Mendelian randomization studies of risk and protective factors for osteoporosis: a systematic review and meta-analysis.Frontiers in endocrinology · 2024Pooled it
- Nonalcoholic fatty liver disease and osteoporosis: a systematic review and meta-analysis.Journal of bone and mineral metabolism · 2017Pooled it
- Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease.Journal of bone and mineral metabolism · 2016Trial
- The contested association between MASLD and osteoporosis: a narrative review of heterogeneous evidence and modifying factors.Archives of osteoporosis · 2026Review
- Effects of Metabolic Dysfunction-Associated Steatotic Liver Disease on Bone Density and Fragility Fractures: Associations and Mechanisms.Journal of obesity & metabolic syndrome · 2024Review
- Association of TNF-α, IGF-1, and IGFBP-1 levels with the severity of osteopenia in mice with nonalcoholic fatty liver disease.Journal of orthopaedic surgery and research · 2023Article
- Osteosarcopenia in NAFLD/MAFLD: An Underappreciated Clinical Problem in Chronic Liver Disease.International journal of molecular sciences · 2023Review
- Non-alcoholic fatty liver disease is associated with decreased bone mineral density in upper Egyptian patients.Scientific reports · 2023Article
- Article
- Causal association of NAFLD with osteoporosis, fracture and falling risk: a bidirectional Mendelian randomization study.Frontiers in endocrinology · 2023Article
- Risk of fractures and subsequent mortality in non-alcoholic fatty liver disease: A nationwide population-based cohort study.Journal of internal medicine · 2022Article
- The association of nonalcoholic fatty liver disease with bone mineral density in type 2 diabetes.European journal of medical research · 2022Article
- Influence of lecithin cholesterol acyltransferase alteration during different pathophysiologic conditions: A 45 years bibliometrics analysis.Frontiers in pharmacology · 2022Article
- Prevalence and Trends in Low Bone Density, Osteopenia and Osteoporosis in U.S. Adults With Non-Alcoholic Fatty Liver Disease, 2005-2014.Frontiers in endocrinology · 2021Article
- Novel insights into the relationship between nonalcoholic fatty liver disease and osteoporosis.Clinical interventions in aging · 2018Review
- Circulating Ferritin in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis.Journal of clinical and experimental hepatologyReview
- EVALUATION OF NON-ALCOHOLIC FATTY LIVER DISEASE AND BONE MINERAL DENSITY IN POSTMENOPAUSAL WOMEN.Acta endocrinologica (Bucharest, Romania : 2005)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo determine the relationship between non-alcoholic steatohepatitis (NASH) and bone mineral density (BMD).
methodsA total of 38 patients (25 males) with a diagnosis of histologically proven NASH and 42 healthy controls (24 males) were enrolled in the study. Demographic features, clinical findings, complete blood count and routine biochemical analysis, as well as adrenal, thyroid and gonadal functions, were recorded. Additionally, intact parathormone, 25-OH-vitamin-D3, tumor necrosis factor-α, interleukin-6, interleukin-1, insulin-like growth factor-1 and insulin-like growth factor binding protein-3 levels were measured in both groups. Furthermore, lumbar spine and femoral neck BMD of both groups were measured by the dual-energy X-ray absorptiometry (DXA) method.
resultsThe mean age was 41 ± 12 years in the NASH group and 43 ± 11 years in the control group. Among demographic features, waist circumference was significantly larger in the NASH group compared to the control group (P < 0.019). Among laboratory parameters, serum triglyceride (P < 0.008), alanine transaminase (P < 0.0001), aspartate transaminase (P < 0.001), alkaline phosphatase (P < 0.016), gamma glutamyl transferase (P < 0.0001), ferritin (P < 0.001) and 25-OH-vitamin-D3 levels (P < 0.0001) were significantly higher in the NASH group compared to the control group. Lumbar BMD was significantly higher in the NASH group compared to the control group (1.057 ± 0.119 g/cm(2) vs 0.941 ± 0.133 g/cm(2); P < 0.001, respectively). In the NASH group, there was no significant relationship between BMD and fibrosis stage in liver biopsy.
conclusionNASH increases BMD and may be related to an elevated serum 25-OH-vitamin D3 level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.